Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1992 2
1994 1
1995 1
1996 1
1997 1
1998 3
1999 4
2000 5
2001 5
2002 1
2003 2
2004 10
2005 4
2006 8
2007 6
2008 10
2009 6
2010 10
2011 15
2012 16
2013 10
2014 18
2015 15
2016 27
2017 28
2018 13
2019 30
2020 40
2021 46
2022 37
2023 34
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for francesco alone
Your search for Francesco Palone retrieved no results
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Wolchok JD, et al. J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24. J Clin Oncol. 2022. PMID: 34818112 Free PMC article. Clinical Trial.
PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. ...Secondary end points included objective respo …
PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivol …
Recent progress in ITP treatment.
Rodeghiero F. Rodeghiero F. Int J Hematol. 2023 Mar;117(3):316-330. doi: 10.1007/s12185-022-03527-1. Epub 2023 Jan 9. Int J Hematol. 2023. PMID: 36622549 Review.
In a UK trial, combining mycophenolate mofetil with corticosteroids as first line therapy was more effective than corticosteroids alone, but at the cost of worse QoL. No combination, including oseltamivir or all-trans retinoic acid or danazol, resulted in convincing eviden …
In a UK trial, combining mycophenolate mofetil with corticosteroids as first line therapy was more effective than corticosteroids alone
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
BACKGROUND: Bortezomib-based induction followed by high-dose melphalan (200 mg/m(2)) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed mul …
BACKGROUND: Bortezomib-based induction followed by high-dose melphalan (200 mg/m(2)) and autologous stem-cell transplantation (MEL200-ASCT) …
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A, Rijavec E, Grossi F. Indini A, et al. Int J Mol Sci. 2021 Apr 30;22(9):4774. doi: 10.3390/ijms22094774. Int J Mol Sci. 2021. PMID: 33946310 Free PMC article. Review.
Clinicaltrials.gov was searched to identify ongoing clinical trials of T-DXd alone or in combination in solid tumors....
Clinicaltrials.gov was searched to identify ongoing clinical trials of T-DXd alone or in combination in solid tumors....
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Chesney JA, et al. J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23. J Clin Oncol. 2023. PMID: 35998300 Free PMC article. Clinical Trial.
Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone....
Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone....
Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery.
Ahmed IIK, De Francesco T, Rhee D, McCabe C, Flowers B, Gazzard G, Samuelson TW, Singh K; HORIZON Investigators. Ahmed IIK, et al. Ophthalmology. 2022 Jul;129(7):742-751. doi: 10.1016/j.ophtha.2022.02.021. Epub 2022 Feb 23. Ophthalmology. 2022. PMID: 35218867 Clinical Trial.
PURPOSE: To present the 5-year results of the HORIZON trial comparing cataract surgery (CS) combined with an intracanalicular microstent with CS alone. DESIGN: Prospective, multicenter, controlled randomized clinical trial. ...No clinical or statistically significant diffe …
PURPOSE: To present the 5-year results of the HORIZON trial comparing cataract surgery (CS) combined with an intracanalicular microstent wit …
Dietary modifications for infantile colic.
Gordon M, Biagioli E, Sorrenti M, Lingua C, Moja L, Banks SS, Ceratto S, Savino F. Gordon M, et al. Cochrane Database Syst Rev. 2018 Oct 10;10(10):CD011029. doi: 10.1002/14651858.CD011029.pub2. Cochrane Database Syst Rev. 2018. PMID: 30306546 Free PMC article.
SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs evaluating the effects of dietary modifications, alone or in combination, for colicky infants younger than four months of age versus another intervention or placebo. ...
SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs evaluating the effects of dietary modifications, alone or in c …
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Dummer R, et al. J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14. J Clin Oncol. 2022. PMID: 35030011 Free PMC article. Clinical Trial.
PURPOSE: Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence s …
PURPOSE: Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have sup …
Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial.
Pivetta E, Goffi A, Nazerian P, Castagno D, Tozzetti C, Tizzani P, Tizzani M, Porrino G, Ferreri E, Busso V, Morello F, Paglieri C, Masoero M, Cassine E, Bovaro F, Grifoni S, Maule MM, Lupia E; Study Group on Lung Ultrasound from the Molinette and Careggi Hospitals. Pivetta E, et al. Eur J Heart Fail. 2019 Jun;21(6):754-766. doi: 10.1002/ejhf.1379. Epub 2019 Jan 28. Eur J Heart Fail. 2019. PMID: 30690825 Free article. Clinical Trial.

Addition of LUS had higher accuracy [area under the receiver operating characteristic curve (AUC) 0.95] than clinical evaluation alone (AUC 0.88) in identifying ADHF (P < 0.01). In contrast, use of CXR/NT-proBNP did not significantly increase the accuracy of clinical ev

Addition of LUS had higher accuracy [area under the receiver operating characteristic curve (AUC) 0.95] than clinical evaluation alone
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Vergote I, et al. Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. Eur J Cancer. 2021. PMID: 34597975 Free article. Clinical Trial.
Adding bevacizumab to olaparib was associated with a numerical improvement in PFS compared with olaparib alone (hazard ratio [HR] 0.71; 95% confidence interval [CI] 0.45-1.09). ...CONCLUSIONS: Results of this hypothesis-generating PA-ITC analysis support the use of mainten …
Adding bevacizumab to olaparib was associated with a numerical improvement in PFS compared with olaparib alone (hazard ratio [HR] 0.7 …
375 results